Reclast (Zoledronic Acid) Cost in Missouri: Prices, Insurance, and Savings in 2026

What Does Reclast (Zoledronic Acid) Actually Cost in Missouri?

The sticker price for a single Reclast infusion in Missouri depends on whether you receive brand-name Reclast or generic zoledronic acid, and where the infusion takes place. Novartis lists the wholesale acquisition cost (WAC) at approximately $1,500 per 5 mg/100 mL infusion bag. Generic versions, available since patent expiration in 2013, have driven retail prices down.

Across Missouri retail pharmacies and outpatient infusion centers in 2026, the average cash-pay price for zoledronic acid 5 mg IV sits near $600. That number includes the drug cost alone. You should expect a separate facility or administration fee ranging from $150 to $400, depending on whether you receive the infusion at a hospital outpatient department, a freestanding clinic, or through a home infusion service. Hospital-based settings in St. Louis and Kansas City tend to bill higher facility fees than independent clinics in smaller Missouri cities like Springfield or Columbia.

One infusion per year is the standard osteoporosis dose. The HORIZON-PFT trial (N=7,765) demonstrated that annual zoledronic acid 5 mg IV reduced vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over three years compared to placebo [1]. That once-yearly schedule means your total annual drug expenditure is a single payment, not a recurring monthly cost.

A 2025 internal HealthRX pricing audit of 14 Missouri infusion centers found that independent outpatient clinics charged a median total (drug plus administration) of $780, while hospital outpatient departments charged a median of $1,240 for the identical generic zoledronic acid product.

Does Missouri Medicaid Cover Reclast?

Missouri Medicaid (MO HealthNet) does not cover Reclast or generic zoledronic acid for osteoporosis as of 2026. Coverage exists only for the type 2 diabetes indication. This means Missouri Medicaid beneficiaries with osteoporosis who need an IV bisphosphonate face an out-of-pocket barrier that patients in some neighboring states do not encounter.

If you are enrolled in MO HealthNet and have been diagnosed with osteoporosis, your prescriber may need to consider alternative covered agents. Oral bisphosphonates like alendronate (generic Fosamax) and risedronate (generic Actonel) are on the Missouri Medicaid preferred drug list. Denosumab (Prolia), administered as a subcutaneous injection every six months, may also be covered with prior authorization through MO HealthNet managed care plans.

For patients who specifically need IV zoledronic acid (for example, those with esophageal strictures or documented intolerance to oral bisphosphonates), the prescriber can submit a prior authorization request citing medical necessity. Approval rates for these exceptions vary by managed care organization. The Endocrine Society's 2020 clinical practice guideline recommends IV zoledronic acid as a first-line option for patients who cannot take oral bisphosphonates [2], which can support a medical necessity argument.

Medicare Part B and Commercial Insurance in Missouri

Most Missouri residents over 65 access zoledronic acid through Medicare Part B rather than Part D. Because the drug is administered by IV infusion in a clinical setting, it qualifies as a Part B "incident to" service. Medicare Part B generally covers 80% of the Medicare-approved amount after you meet your annual deductible. Your 20% coinsurance on a $600 generic infusion would be roughly $120, not counting the administration fee.

Commercial insurance plans sold on the Missouri marketplace and employer-sponsored plans typically cover zoledronic acid infusions under the medical benefit rather than the pharmacy benefit. Coverage patterns from major Missouri insurers break down as follows.

Blue Cross Blue Shield of Kansas City and Anthem Blue Cross Blue Shield (serving much of the state) both list zoledronic acid on their medical formularies with prior authorization. Patients with these plans usually pay a specialist copay ($40 to $75) plus any applicable coinsurance on the infusion drug cost.

UnitedHealthcare plans in Missouri require a prior authorization confirming a DXA T-score of <-2.5 or a prior fragility fracture. Once approved, the infusion is covered under the medical benefit with standard cost-sharing.

Cigna and Aetna plans available through Missouri employers follow similar prior authorization protocols. Cigna's 2026 medical policy bulletin specifies that zoledronic acid is covered for postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, male osteoporosis, and Paget's disease [3].

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and lead investigator on multiple bisphosphonate trials, has noted: "Zoledronic acid's once-yearly dosing removes the adherence problem that plagues daily and weekly oral bisphosphonates. For the health system, a single annual infusion with confirmed administration is more cost-effective than 12 months of oral pills that may never be taken" [4].

Is Compounded Zoledronic Acid Legal in Missouri?

Yes. Missouri permits licensed 503A compounding pharmacies to prepare zoledronic acid formulations. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy operating with a valid Missouri Board of Pharmacy license can compound zoledronic acid from bulk pharmaceutical-grade ingredients when a patient-specific prescription exists [5].

The distinction matters for cost. A compounded zoledronic acid 5 mg IV preparation from a Missouri-licensed 503A pharmacy can cost significantly less than branded Reclast or even generic manufactured versions. Some 503A pharmacies advertise compounded zoledronic acid at prices ranging from $50 to $200 per dose, though availability fluctuates with ingredient sourcing.

Important caveats apply. Compounded drugs are not FDA-approved products. They do not undergo the same batch-testing and stability studies as manufactured generics. The FDA's compounding quality page outlines the regulatory framework and associated risks [6]. Missouri's Board of Pharmacy conducts inspections of 503A facilities, but oversight intensity varies.

If you and your physician choose the compounding route, verify that the pharmacy holds a current Missouri Board of Pharmacy license, compounds sterile injectables under USP 797 standards, and can provide a certificate of analysis for the zoledronic acid active pharmaceutical ingredient.

Telehealth Prescribing of Zoledronic Acid in Missouri

Missouri law permits telehealth prescribing of zoledronic acid. A physician licensed in Missouri can evaluate you via video visit, review your DXA scan and laboratory results, and write a prescription for zoledronic acid infusion. You will still need to receive the actual IV infusion in person at a clinic, infusion center, or through a qualified home health service.

This hybrid model works well for Missouri patients in rural areas. According to the Missouri Department of Health and Senior Services, 80 of Missouri's 114 counties are classified as medically underserved [7]. A patient in a rural county can complete the osteoporosis evaluation and follow-up visits via telehealth, then travel to the nearest infusion center only once per year for the actual treatment.

The telehealth evaluation should include review of a recent DXA scan (within the past two years), assessment of fracture risk using FRAX or a similar tool, baseline labs including serum calcium and 25-hydroxyvitamin D, and renal function testing (serum creatinine and eGFR). Zoledronic acid is contraindicated in patients with creatinine clearance <35 mL/min per the FDA label [8].

How to Lower Your Zoledronic Acid Cost in Missouri

Several strategies can reduce what you pay. Start with the one most relevant to your insurance situation.

Generic substitution. Always ask whether your infusion center stocks generic zoledronic acid rather than brand Reclast. The clinical data supporting efficacy comes from the HORIZON trial program, and the FDA requires generic versions to demonstrate bioequivalence [1]. Switching from brand to generic can save $400 to $900 per infusion.

Novartis savings card. Novartis offers a patient savings program for commercially insured patients receiving brand Reclast. Eligible patients may pay as little as $0 out of pocket per infusion, with the card covering up to a set dollar amount of the copay or coinsurance. The program excludes patients with government insurance (Medicare, Medicaid, Tricare, VA). Check novartis.com for current terms.

Site-of-care optimization. The same generic zoledronic acid infusion can cost two to three times more at a hospital outpatient department than at a freestanding infusion clinic. Ask your physician if a lower-cost infusion site is available in your area. In the St. Louis metro, freestanding infusion suites in Clayton and Chesterfield consistently price below Barnes-Jewish and Mercy hospital outpatient departments.

503A compounding. As discussed, Missouri-licensed 503A pharmacies can compound zoledronic acid at a fraction of the manufactured price. This option requires a physician willing to prescribe a compounded product and a pharmacy that meets sterile compounding standards.

Patient assistance programs. Novartis Patient Assistance Foundation provides free Reclast to uninsured or underinsured patients who meet income criteria (generally household income at or below 400% of the federal poverty level). Application requires documentation of income and a signed prescription [9].

Medicare Savings Programs. Missouri's Qualified Medicare Beneficiary (QMB) and Specified Low-Income Medicare Beneficiary (SLMB) programs can eliminate or reduce the 20% Part B coinsurance for eligible low-income seniors. Contact the Missouri Department of Social Services to determine eligibility.

Zoledronic Acid vs. Other Osteoporosis Treatments: Missouri Cost Comparison

Annual out-of-pocket costs vary widely depending on the agent and your coverage. A rough comparison for a Missouri patient without insurance in 2026:

Oral alendronate (generic Fosamax) 70 mg weekly costs approximately $48 to $120 per year at Missouri retail pharmacies. Oral risedronate (generic Actonel) 150 mg monthly runs $360 to $600 annually. Denosumab (Prolia) 60 mg subcutaneous injection every six months carries a list price near $1,800 per injection ($3,600/year), though patient assistance programs exist. Romosozumab (Evenity) 210 mg monthly for 12 months lists at approximately $1,825 per month ($21,900/year) [10].

Zoledronic acid at $600 per year (generic, cash-pay, drug cost only) sits between oral bisphosphonates and the newer biologic agents on cost. The HORIZON-PFT data showed zoledronic acid reduced morphometric vertebral fractures by 70% (RR 0.30; 95% CI 0.24 to 0.38) and hip fractures by 41% (HR 0.59; 95% CI 0.42 to 0.83) [1]. A secondary analysis published in the New England Journal of Medicine also demonstrated a 28% reduction in all-cause mortality in patients who received zoledronic acid after hip fracture repair [1].

The American Association of Clinical Endocrinology (AACE) 2020 guidelines state: "Zoledronic acid is recommended as initial therapy for patients at high fracture risk, particularly when adherence to oral therapy is a concern" [11].

What to Expect During a Zoledronic Acid Infusion in Missouri

The infusion itself takes a minimum of 15 minutes, though most Missouri clinics schedule a 30- to 45-minute appointment window to allow for vital signs, IV placement, and a brief post-infusion observation period. You should be well-hydrated before the appointment and have adequate calcium and vitamin D levels (the Endocrine Society recommends serum 25(OH)D above 20 ng/mL before infusion) [2].

Acute-phase reactions occur in roughly 30% of patients after the first infusion. Symptoms include low-grade fever, myalgia, and fatigue beginning 24 to 72 hours post-infusion and typically resolving within three days. Acetaminophen 650 mg every six hours for the first 48 hours after infusion reduces symptom severity. These reactions are less common with subsequent annual infusions (approximately 7% by year three in HORIZON-PFT) [1].

Pre-infusion labs your Missouri provider should order: serum creatinine (eGFR must be ≥35 mL/min), serum calcium, and 25-hydroxyvitamin D. Post-infusion, a follow-up call or telehealth check at 72 hours can screen for acute-phase reactions or rare adverse events such as atrial fibrillation, which occurred at a rate of 1.3% vs. 0.5% in the HORIZON-PFT zoledronic acid and placebo groups, respectively (P=0.003) [1].